Skip to content

BBNX BBNX EBITDA

EBITDA at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$12.93M+88.9%
AdaptHealth logo
AdaptHealthAHCO
$111.96M-4.7%
Insulet logo
InsuletPODD
Medtronic logo
MedtronicMDT
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Calculated from BBNX’s reported figures.

$24.3Mebit+
$585.0KDepreciation Depletion & Amortization
=-$23.69M

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's EBITDA?
BBNX (BBNX) reported EBITDA of -$23.69M in Q1 2026.
How has BBNX's EBITDA changed year-over-year?
BBNX's EBITDA decreased by 29.2% year-over-year, from -$18.34M to -$23.69M.
What is the long-term trend for BBNX's EBITDA?
Over 2 years (2023 to 2025), BBNX's EBITDA has grown at a 42.3% compound annual growth rate (CAGR), from -$34.62M to -$70.11M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.